Interleukin-22: a likely target for treatment of autoimmune diseases

Autoimmun Rev. 2014 Jun;13(6):615-20. doi: 10.1016/j.autrev.2013.11.008. Epub 2014 Jan 10.

Abstract

Interleukin-22 (IL-22) is a member of IL-10 family cytokines that is produced by many different types of lymphocytes including both those of the innate and adaptive immune systems. This includes activated T cells, most notably Th17 and Th22 cells, and NK cells, γδ T cells, LTi cells and LTi-like cells. IL-22 mediates its effects via the IL-22-IL-22R complex and subsequent Janus kinase-signal transducer and activators of transcription (JAK-STAT) signaling pathway. Recently accumulated evidence has indicated that IL-22 also plays an important role in the pathogenesis of many autoimmune diseases. In this review, we discuss the recent findings and advancement of the role for IL-22 in several autoimmune diseases, such as psoriasis, rheumatoid arthritis (RA), hepatitis, graft versus host disease (GHVD) and allergic diseases, implicating that target IL-22 may have a therapeutic potential in those autoimmune diseases.

Keywords: Autoimmunity; Cytokine receptor; Innate immunity; Interleukin-22; Signal pathway; T-helper cell.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Autoimmune Diseases / immunology*
  • Humans
  • Interleukin-17 / immunology
  • Interleukin-17 / metabolism
  • Interleukins / immunology*
  • Interleukins / therapeutic use
  • Receptors, Interleukin / immunology
  • Signal Transduction / immunology
  • T-Lymphocytes, Helper-Inducer / immunology

Substances

  • Interleukin-17
  • Interleukins
  • Receptors, Interleukin
  • interleukin-22 receptor
  • interleukin-22